H-1B visa programme faces onslaught of Congressional bills

March 9, 2017

Washington, Mar 9: With the Trump administration seriously mulling H-1B visa reforms, at least half a dozen bills have been tabled in the US House of Representatives and the Senate, contending that the programme that is popular among Indian IT firms eats into American jobs.

visaAuthors of all these bills from both the Republican and the Democratic parties believe that H-1B work visas, which are highly popular among Indian techies and Indian IT companies, tend to replace American workers.

Even though this argument is disputed by research scholars, economists and Silicon Valley executives, these legislations are based on the premise that Indian techies are eating into American jobs.

In less than a week of Trump being sworn in as the 45th US President, Republican Senator Chuck Grassley, and Assistant Senate Minority Leader Dick Durbin, introduced the "H-1B and L-1 Visa Reform Act" to prioritise American workers and restore fairness in visa programmes for skilled workers.

Grassley is Chairman of the powerful Senate Judiciary Committee. Among other things, the H1-B reform bill proposes to eliminate the lottery system and give foreign students educated in the US priority on visas.

The bill would prohibit companies with more than 50 employees, of which at least half are H-1B or L-1 holders, from hiring additional H-1B employees.

It also explicitly prohibits the replacement of American workers by H-1B or L-1 visa holders. The bill among other things would also crackdown on outsourcing companies that import large numbers of H-1B and L-1 workers for temporary training purposes only to send the workers back to their home countries to do the same job.

Specifically, it would prohibit companies with more than 50 employees of which at least half are H-1B or L-1 holders, from hiring additional H-1B employees, a statement said.

It explicitly prohibits the replacement of American workers by H-1B or L-1 visa holders. These provisions address the types of abuses that have been well-documented in recent press reports.

Democrat Zoe Lofgren -- who represents a Congressional district in California that includes Silicon Valley -- introduced 'The High-Skilled Integrity and Fairness Act of 2017'.

As soon as the bill, which proposes a skill and wage- based system for allocation of H-1B visas and seeks to more than double the minimum wage for an H-1B visa holder to USD 130,000, was introduced, stocks of major Indian information technology went down and rattled the USD 150-billion outsourcing industry.

"It's near-impossible to design an immigration system that selects only the highest-paid and still protects the inventiveness and meritocracy that has made Silicon Valley the centre of the tech world," said Ridhika Batra, US-head of the Federation of Indian Chambers of Commerce and Industries.

"Like all forms of protectionism, these measures by (the) US government would only lower standards and reduce productivity, eventually causing the US to lose the edge -- and the income -- that comes with being the undisputed champion of innovation," she said.

The bill among other things proposes setting aside 20 per cent of the annual allocation of H-1B visas for small and start-up employers with 50 or fewer employees.

Utah Republican Representative Jason Chaffetz, and his party colleague in the Senate Senator Mike Lee, have introduced identical bills in the House and the Senate -- Fairness for High-Skilled Immigrants Act of 2017 -- which proposes to eliminate the per-country immigration caps with a first-come-first-served system.

On February 2, Senator Sherrod Brown joined by Joe Donnelly and Kirsten Gillibrand, introduced the "End Outsourcing Act," which aims to ensure that federal contracts are awarded to companies who hire American workers.

Two Republican Senators Tom Cotton and David Perdue unveiled the Reforming American Immigration for Strong Employment (RAISE) Act on February 7, which proposes to lower overall immigration to 637,960 in its first year and to 539,958 by its tenth year -- a 50 per cent reduction from the 1,051,031 immigrants who arrived in 2015.

Cotton and Perdue met Trump at the White House on Tuesday, after which they said that H-1B and employment-based Green Card is likely to be reformed to attract the best and the brightest from across the world.

The White House yesterday said the Trump Administration has a natural desire to have a comprehensive look at the H-1B, spousal visa and students visas. Last week, Indian-American Congressman Ro Khanna joined a bipartisan group of three other lawmakers to table a legislation to reform the current H-1B and L1 work visas and end its abuse by foreign companies.

The bill, if passed by both the House and the Senate and signed into law by the US President, would require employers to make a good faith effort to recruit and hire American workers before bringing in foreign workers.

It also prohibits employers from replacing American workers with H-1B and L-1 workers or giving preference to H-1B visa holders when they are filling open positions. It will modify existing H-1B wage requirements, and establishes wage requirements for L-1 workers.

The bill proposes to prohibit employers from outsourcing H-1B and L-1 visa holders to other sites unless the employer obtains a waiver which is available only in limited circumstances when the rights of American workers are protected.

Congressional experts note that it might not be easy to pass a bill on H-1B visas unless there is a consensus or broader agreement on comprehensive immigration reform.

Batra said it is important to deal carefully the underlying shortage of STEM-skilled workers. According to a latest Brookings study by 2020, demand for skilled technologists will exceed the number of qualified applicants by 1 million, leaving USA vulnerable in key areas such as technological innovation, economic development and cybersecurity.

"Moving the allocation decision from an arbitrary process to a market-clearing auction should settle the debate over our economy's demand for skilled immigrant labour, and an incremental success in our highly controversial immigration debate might help break the immigration reform impasse in other areas, as well," Batra said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
January 25,2020

Pentagon, Jan 25: Thirty-four US troops had been diagnosed with concussions and traumatic brain injury (TBI) as a result of the January 8 Iranian missile attack on two military bases in Iraq housing American soldiers, the Pentagon said.

"Eight service members who were previously transported to Germany have been brought to the US, they would continue to receive treatment in the US either at Walter Reed or their home bases," Pentagon spokesman Jonathan Hoffman told the media on Friday.

Hoffman said that nine service members were still undergoing treatment in Germany, and the rest of the 17 injured troops have already returned to duty in Iraq, reports Xinhua news agency.

Lat week, the US military had said that 11 service members were treated for concussion symptoms due to the missile attacks.

Hoffman noted that the symptoms "are late developing and manifested over a period of time".

In retaliation for the killing of Iranian Major General Qasem Soleimani in an American drone attack on January 3 in Baghdad, Tehran launched over 13 ballistic missiles on the two military bases in Anbar and near the city of Erbil.

US military initially said that no casualty was reported from the Iranian attack. President Donald Trump then downplayed the seriousness of those injures.

"I heard that they had headaches and a couple of other things, but I would say and I can report that it's not very serious," Trump told reporters on Wednesday at a press conference in Davos, Switzerland.

More than 5,000 US troops are deployed in Iraq to support the country's forces in the battle against Islamic State militants.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 13,2020

Mexico City, Jun 13: The number of people, who have died of COVID-19 in Mexico, has risen by 544 to 16,448 within the past 24 hours, Jose Luis Alomia, the director of epidemiology at the Health Ministry, said.

He also said on late Friday that the number of confirmed coronavirus cases had increased by 5,222 to 139,196 within the same period of time.

A day earlier, the Latin American nation has recorded 4,790 new confirmed cases of the coronavirus, with 587 fatalities.

The World Health Organization declared the COVID-19 outbreak a pandemic on March 11. To date, more than 7.6 million people have been infected with the coronavirus worldwide, with over 425,000 fatalities, according to Johns Hopkins University.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.